FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research
Archives of Women's Mental Health · 2024
DOI: 10.1007/s00737-024-01456-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Women's Mental Health, 2024. Verfasst von Priya Rani und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Ziauddin University, Karachi, Pakistan. Hauptthemen laut MEDLINE: Hot Flashes, Menopause. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Women going through menopause frequently experience vasomotor symptoms such as hot flashes, night sweats, and sleep disturbances, significantly influencing their quality of life. Hormonal therapy has been demonstrated to be beneficial in treating VMS. However, due to specific restrictions, it is not recommended for every woman. Fezolinetant, a neurokinin 3 antagonist and non-hormonal treatment for severe to moderate VMS, functions by inhibiting neuronal impulses originating from the hypothalamic thermoregulatory center. Current Skylight 2 and 4 trials statistically demonstrate the safety and acceptability of fezolinetant, with relatively few adverse effects reported. Fezolinetant has been shown great potential for treating menopausal-related VMS, supporting its further advancement. However, further investigation is required to thoroughly evaluate its safety, effectiveness, and its impact on sleep patterns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Ziauddin University, Karachi, Pakistan.
- Department of Internal Medicine, Jinnah Sindh Medical University, Karachi, Pakistan.
- Department of Internal Medicine, Karachi Medical and Dental University, Karachi, Pakistan.
- Department of Internal Medicine, Dow University of Health Sciences, Baba-e-Urdu Road, Karachi, Pakistan. doultanipayal2002@gmail.com.
Zitieren
APA
Rani, P., Zehra, D., Mansoor, M., & Rani, P. (2024). FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research. Archives of Women's Mental Health. https://doi.org/10.1007/s00737-024-01456-y
Vancouver
Rani P, Zehra D, Mansoor M, Rani P. FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research. Archives of Women's Mental Health. 2024. doi:10.1007/s00737-024-01456-y
BibTeX
@article{Rani2024,
author = {Rani, Priya and Zehra, Dua and Mansoor, Malaika and Rani, Payal},
title = {FDA approved fezolinetant (Veozah): a critical evaluation of its efficacy and safety for menopausal vasomotor symptoms, calling for prospective research},
journal = {Archives of Women's Mental Health},
year = {2024},
doi = {10.1007/s00737-024-01456-y}
}
EUVIMED